These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Static Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141 [TBL] [Abstract][Full Text] [Related]
3. Multiparametric Analysis Combining DSC-MR Perfusion and [18F]FET-PET is Superior to a Single Parameter Approach for Differentiation of Progressive Glioma from Radiation Necrosis. Panholzer J; Malsiner-Walli G; Grün B; Kalev O; Sonnberger M; Pichler R Clin Neuroradiol; 2024 Jun; 34(2):351-360. PubMed ID: 38157019 [TBL] [Abstract][Full Text] [Related]
7. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study. Bashir A; Brennum J; Broholm H; Law I J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154 [TBL] [Abstract][Full Text] [Related]
8. The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers. Skoblar Vidmar M; Doma A; Smrdel U; Zevnik K; Studen A Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743228 [TBL] [Abstract][Full Text] [Related]
9. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. Filss CP; Galldiks N; Stoffels G; Sabel M; Wittsack HJ; Turowski B; Antoch G; Zhang K; Fink GR; Coenen HH; Shah NJ; Herzog H; Langen KJ J Nucl Med; 2014 Apr; 55(4):540-5. PubMed ID: 24578243 [TBL] [Abstract][Full Text] [Related]
10. Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression. Müller M; Winz O; Gutsche R; Leijenaar RTH; Kocher M; Lerche C; Filss CP; Stoffels G; Steidl E; Hattingen E; Steinbach JP; Maurer GD; Heinzel A; Galldiks N; Mottaghy FM; Langen KJ; Lohmann P J Neurooncol; 2022 Sep; 159(3):519-529. PubMed ID: 35852737 [TBL] [Abstract][Full Text] [Related]
11. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma. Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307 [TBL] [Abstract][Full Text] [Related]
13. Static and dynamic Verger A; Stoffels G; Bauer EK; Lohmann P; Blau T; Fink GR; Neumaier B; Shah NJ; Langen KJ; Galldiks N Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):443-451. PubMed ID: 29043400 [TBL] [Abstract][Full Text] [Related]
14. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540 [TBL] [Abstract][Full Text] [Related]
15. Differentiating high-grade glioma progression from treatment-related changes with dynamic [ Rozenblum L; Zaragori T; Tran S; Morales-Martinez A; Taillandier L; Blonski M; Rech F; Galanaud D; Kas A; Verger A Eur Radiol; 2023 Apr; 33(4):2548-2560. PubMed ID: 36367578 [TBL] [Abstract][Full Text] [Related]
17. Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI. Werner JM; Stoffels G; Lichtenstein T; Borggrefe J; Lohmann P; Ceccon G; Shah NJ; Fink GR; Langen KJ; Kabbasch C; Galldiks N Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1889-1901. PubMed ID: 31203420 [TBL] [Abstract][Full Text] [Related]
19. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047 [TBL] [Abstract][Full Text] [Related]
20. Detection of recurrent high-grade glioma using microstructure characteristics of distinct metabolic compartments in a multimodal and integrative 18F-FET PET/fast-DKI approach. Lohmeier J; Radbruch H; Brenner W; Hamm B; Hansen B; Tietze A; Makowski MR Eur Radiol; 2024 Apr; 34(4):2487-2499. PubMed ID: 37672058 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]